Cancer Research Cancer Epigenetics EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, J.
Right arrow Articles by Jooss, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, J.
Right arrow Articles by Jooss, K.
[Cancer Research 65, 6901-6909, August 1, 2005]
© 2005 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Inhibition of Lymphogenous Metastasis Using Adeno-Associated Virus-Mediated Gene Transfer of a Soluble VEGFR-3 Decoy Receptor

JianMin Lin1, Alshad S. Lalani1, Thomas C. Harding1, Melissa Gonzalez1, Wei-Wei Wu1, Bo Luan1, Guang Huan Tu1, Kathryn Koprivnikar1, Melinda J. VanRoey1, Yulong He2, Kari Alitalo2 and Karin Jooss1

1 Department of Preclinical Oncology and Immunology, Cell Genesys, Inc., South San Francisco, California and 2 Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Haartman Institute, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland

Requests for reprints: JianMin Lin, Department of Preclinical Oncology and Immunology, Cell Genesys, Inc., 500 Forbes Boulevard, South San Francisco, CA 94080. Phone: 650-266-2911; Fax: 650-266-3300; E-mail: jianmin.lin{at}cellgenesys.com.

The presence of metastases in regional lymph nodes is a strong indicator of poor patient survival in many types of cancer. It has recently been shown that the lymphangiogenic growth factor, vascular endothelial growth factor-C (VEGF-C), and its receptor, VEGF receptor-3 (VEGFR3), may play a pivotal role in the promotion of metastasis to regional lymph nodes. In this study, human prostate and melanoma tumor models that preferentially metastasize to the lymph nodes following s.c. tumor cell implantation were established from lymph node metastases via in vivo selection. Melanoma tumor cell sublines established from lymph node metastasis express higher amounts of VEGF-C than the parental tumor cells. The inhibition of tumor-derived VEGF-C with a soluble VEGFR3 decoy receptor, sVEGFR3-Fc, expressed via a recombinant adeno-associated viral vector, potently blocks tumor-associated lymphangiogenesis and tumor metastasis to the lymph nodes, when the treatment was initiated before the tumor implantation. In addition, sVEGFR3-Fc serum levels required for efficient blockade of lymph node metastases are strictly dependent on the VEGF-C levels generated by the primary tumor. Recombinant adeno-associated virus–mediated gene transfer of sVEGFR3-Fc may represent a feasible therapeutic strategy for blockade of lymphogenous metastasis.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Vallania, D. Schiavone, S. Dewilde, E. Pupo, S. Garbay, R. Calogero, M. Pontoglio, P. Provero, and V. Poli
Genome-wide discovery of functional transcription factor binding sites by comparative genomics: The case of Stat3
PNAS, March 31, 2009; 106(13): 5117 - 5122.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Schomber, A. Zumsteg, K. Strittmatter, I. Crnic, H. Antoniadis, A. Littlewood-Evans, J. Wood, and G. Christofori
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis
Mol. Cancer Ther., January 1, 2009; 8(1): 55 - 63.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. B. Burton, S. J. Priceman, J. L. Sung, E. Brakenhielm, D. S. An, B. Pytowski, K. Alitalo, and L. Wu
Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis
Cancer Res., October 1, 2008; 68(19): 7828 - 7837.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Ganesh, M. Gonzalez-Edick, D. Gibbons, M. Van Roey, and K. Jooss
Intratumoral Coadministration of Hyaluronidase Enzyme and Oncolytic Adenoviruses Enhances Virus Potency in Metastatic Tumor Models
Clin. Cancer Res., June 15, 2008; 14(12): 3933 - 3941.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
J. M. Bock, L. L. Sinclair, N. S. Bedford, R. E. Jackson, J. H. Lee, and D. K. Trask
Modulation of Cellular Invasion by VEGF-C Expression in Squamous Cell Carcinoma of the Head and Neck
Arch Otolaryngol Head Neck Surg, April 1, 2008; 134(4): 355 - 362.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
S. Choi and J.N. Myers
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Journal of Dental Research, January 1, 2008; 87(1): 14 - 32.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Sundar and T. S. Ganesan
Role of Lymphangiogenesis in Cancer
J. Clin. Oncol., September 20, 2007; 25(27): 4298 - 4307.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. P. Padera, M. Ancukiewicz, T. Hoshida, D. Fukumura, and R. K. Jain
Anti-VEGFR-3 Therapy and Lymph Node Metastasis
Cancer Res., May 15, 2007; 67(10): 5055 - 5055.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Ganesh, M. Gonzalez Edick, N. Idamakanti, M. Abramova, M. VanRoey, M. Robinson, C.-O. Yun, and K. Jooss
Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing Mice
Cancer Res., May 1, 2007; 67(9): 4399 - 4407.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. Goldman, J. M. Rutkowski, J. D. Shields, M. C. Pasquier, Y. Cui, H. G. Schmokel, S. Willey, D. J. Hicklin, B. Pytowski, and M. A. Swartz
Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis
FASEB J, April 1, 2007; 21(4): 1003 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Hirakawa, L. F. Brown, S. Kodama, K. Paavonen, K. Alitalo, and M. Detmar
VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites
Blood, February 1, 2007; 109(3): 1010 - 1017.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Laakkonen, M. Waltari, T. Holopainen, T. Takahashi, B. Pytowski, P. Steiner, D. Hicklin, K. Persaud, J. R. Tonra, L. Witte, et al.
Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth
Cancer Res., January 15, 2007; 67(2): 593 - 599.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Wissmann and M. Detmar
Pathways Targeting Tumor Lymphangiogenesis
Clin. Cancer Res., December 1, 2006; 12(23): 6865 - 6868.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Li, A. S. Lalani, T. C. Harding, B. Luan, K. Koprivnikar, G. Huan Tu, R. Prell, M. J. VanRoey, A. D. Simmons, and K. Jooss
Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF-Secreting Cancer Immunotherapy.
Clin. Cancer Res., November 15, 2006; 12(22): 6808 - 6816.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Zeng, K. Opeskin, J. Goad, and E. D. Williams
Tumor-Induced Activation of Lymphatic Endothelial Cells via Vascular Endothelial Growth Factor Receptor-2 Is Critical for Prostate Cancer Lymphatic Metastasis
Cancer Res., October 1, 2006; 66(19): 9566 - 9575.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Shayan, M. G. Achen, and S. A. Stacker
Lymphatic vessels in cancer metastasis: bridging the gaps
Carcinogenesis, September 1, 2006; 27(9): 1729 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Hoshida, N. Isaka, J. Hagendoorn, E. di Tomaso, Y.-L. Chen, B. Pytowski, D. Fukumura, T. P. Padera, and R. K. Jain
Imaging Steps of Lymphatic Metastasis Reveals That Vascular Endothelial Growth Factor-C Increases Metastasis by Increasing Delivery of Cancer Cells to Lymph Nodes: Therapeutic Implications
Cancer Res., August 15, 2006; 66(16): 8065 - 8075.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. Mazzone and P. M. Comoglio
The Met pathway: master switch and drug target in cancer progression
FASEB J, August 1, 2006; 20(10): 1611 - 1621.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Zhang, E. Giraudo, J. A. Hoffman, D. Hanahan, and E. Ruoslahti
Lymphatic Zip Codes in Premalignant Lesions and Tumors
Cancer Res., June 1, 2006; 66(11): 5696 - 5706.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Roberts, B. Kloos, M. Cassella, S. Podgrabinska, K. Persaud, Y. Wu, B. Pytowski, and M. Skobe
Inhibition of VEGFR-3 Activation with the Antagonistic Antibody More Potently Suppresses Lymph Node and Distant Metastases than Inactivation of VEGFR-2.
Cancer Res., March 1, 2006; 66(5): 2650 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Y. Wong, H. Haack, D. Crowley, M. Barry, R. T. Bronson, and R. O. Hynes
Tumor-Secreted Vascular Endothelial Growth Factor-C Is Necessary for Prostate Cancer Lymphangiogenesis, but Lymphangiogenesis Is Unnecessary for Lymph Node Metastasis
Cancer Res., November 1, 2005; 65(21): 9789 - 9798.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.